



Perspectives and Limitations of Rheumatoid Arthritis Research

Zhang J*

Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Editorial

Rheumatoid arthritis (RA) is a common, systemic, chronic inflammatory autoimmune disease that affects about 1% of the world population [1]. Expenditures for adults with arthritis and other rheumatic conditions run into billions of dollars annually in the United States [2]. The medical doctors and researchers have been trying to find an efficiency approaching to treat RA. However, there is no cure for RA due to the cause of RA is not yet fully understood. It is believed that an abnormal response of the immune system plays a leading role in the inflammation and joint damage that occurs, however, no one knows for sure why and how the immune system goes awry.

The early RA research focused on blood groups. A significant correlation between the absence of the Rh antigen D and rheumatic disease has been reported [3]. Further studies were focused on the descriptive epidemiology and the results indicated that a genetic effect plays an important role in RA development [4]. A high prevalence of RA has been reported in the Pima Indians (5.3%) [5] and in the Chippewa Indians (6.8%) [6]. However, very low occurrences (0.2-0.3%) were found in the populations of China [7] and Japan [8]. There was no any RA case found in 500 adults in South Africa [9] and in 2000 adults in Nigeria [10]. These findings suggested that some genetic risk factors contribute to RA [11,12]. More studies have demonstrated consistently that having a family history of RA increases the risk of developing RA by about 3-5 times [13]. Twin studies have also provided compelling evidence to support this genetic component [14,15].

Modern molecular biological technologies have extended useful approaches for RA research. Recently, gene expression is used as a tool to investigate pathogenesis in RA and provided useful information for understanding RA [16]. RA susceptibility loci were discovered through candidate gene, linkage, and genome-wide association studies (GWAS). The gene signatures in the synovial tissues of RA and osteoarthritis (OA) have been found using microarray approaches [17].

OPEN ACCESS

*Correspondence:

Jianying Zhang, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, 210 Lothrop Street, BST, E1640, Pittsburgh, PA 15213, USA, Tel: 412-383-5302;

Fax: 412-648-8548;

E-mail: jianying@pitt.edu

Received Date: 12 May 2017

Accepted Date: 16 May 2017

Published Date: 22 May 2017

Citation:

Zhang J. Perspectives and Limitations of Rheumatoid Arthritis Research. *Remed Open Access*. 2017; 2: 1057.

Copyright © 2017 Zhang J. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citrullination is a process in which the enzymes called peptidyl arginine deiminases (PADs) transform (citrullinate) proteins within the cells when the cells reach the end of their lifespan. Normally, dying cells do not come in contact with the immune system and are not identified as a potential threat to the body [1]. However, in a RA patient, the immune system loses its ability to distinguish between what belongs to the body and what is foreign to the body. These citrullinated proteins are mistaken as antigens by the immune system. In response to these antigens, the immune system produces anti-citrullinated protein antibody (ACPA). The study on genome-wide markers has shown that the heritability of ACPA-positive RA is around 40%-55% [18]. The presence of ACPA is used as an accurate predictor of RA to predict the disease even before the clinically apparent with joint symptoms [1].

The strongest genetic risk factor for RA is the shared epitope (SE) alleles at HLA-DRB1, where each risk allele is associated with an approximately doubled risk of ACPA-positive RA [19]. In RA patients, an increased expression of HLA-DRB1 has been found in various cell types present in synovial tissue but also in peripheral blood B cells [20]. However, molecular basis for the association between at risk DRB1 alleles and RA remains largely unknown.

Using traditional linkage and candidate gene studies to uncover genetic susceptibility has not led to definitive answers regarding the etiology of RA [12]. The most powerful and extensively employed approach in discovering susceptibility variants for RA and the other complex disease traits is GWAS. GWAS has led to the identification and validation of many novel RA risk alleles. However, the detection of rare variation is still a challenge in current genotyping arrays.

White blood cells are key immune system cells that play a central role in the autoimmune response. The relationship between loss self-tolerance and synovial involvement is unclear at this

time, but synovitis occurs when leukocytes infiltrate the synovium [21]. The mechanism of inflammation in RA caused by white blood cells migration has been studied [22]. It has been reported that fibroblast-like synoviocytes (FLS) play a key role in developing RA [23]. Pathophysiology of RA is controlled by both T and B cells with organized involvement of pro-inflammatory cytokines [24]. The study findings have demonstrated that cytokines are responsible for inflammation and joint destruction during arthritis [25]. Understanding the pivotal role of pro-inflammatory cytokine networks in rheumatoid synovium has led to the identification of tumor necrosis factor α (TNF- α) and interleukin 6 (IL-6) as relevant therapeutic targets. RA was the first disease for which anti-TNF biologics were used [26].

The antibody-based pharmacodelivery of anti-inflammatory cytokines has been used as an alternative therapeutic strategy for RA treatment [27,28]. Recombinant interleukin 4 (IL-4) has been investigated in preclinical models of rheumatoid arthritis, showing disease-modifying efficacy [29]. The immunocytokine F8-IL10 is currently being investigated in clinical trials in patients with active RA [30].

Physical therapy and medications can help slow the disease's progression. Currently, mild cases of RA can be treated with anti-inflammatory medications (NSAIDs). More severe cases of RA can be managed with anti-rheumatic drugs (DMARDs). These therapeutic advances have radically improved the prognosis of patients with RA, and remission is now an achievable objective. However, only a few patients get longstanding remission with treatment [31].

Meta-analysis provides a new tool to combine data from several studies and increase the power of a study to detect novel associations of modest effect. Many novel RA loci have been discovered more recently through meta-analysis [32]. The efficacy and safety of all five currently available TNF-blockers in the treatment of RA have been studied using meta-analysis [33]. The risk of malignancy among patients with RA has also been investigated by meta-analysis [34].

The recent RA research is focused on identification of the disease earlier in the process before extensive joint and bone damage occurs. The achievements of RA research have brought hope for further improvements in the management of RA [1]. The developments in molecular biology and computational chemistry have provided a new approach to design the agents that specifically target pro-inflammatory cytokines. So far, biological agents, such as TNF inhibitors, have shown therapeutic benefit for RA treatment. However, the costs and side effects could be minimized ideally.

Although the RA studies have made exciting progress, there is still a far way for RA research to go. Future research is needed to deepen our understanding of RA disease. We need to know how the body's defenses heredity infection and environment or lifestyle interact to cause RA. We also need to find targeted therapies that maximize efficacy with fewer side effects and lower cost. Studies on gene therapy and stem cell therapy are new challenges for RA research.

References

- Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. *Am J Manag Care*. 2012;18(13 Suppl):S295-302.
- Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Helmick CG. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. *Arthritis and rheumatism*. 2007;56(5):1397-1407.
- Cohen AS, Boyd WC, Goldwasser S, Cathcart ES, Heisler M. Correlation between Rheumatic Diseases and Rh Blood Groups. *Nature*. 1963;200:1215.
- Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. *Arthritis Res*. 2002;4:S265-72.
- Del Puente A, Knowler WC, Pettitt DJ, Bennett PH. High incidence and prevalence of rheumatoid arthritis in Pima Indians. *Am J Epidemiol*. 1989;129(6):1170-8.
- Harvey J, Lotze M, Stevens MB, Lambert G, Jacobson D. Rheumatoid arthritis in a Chippewa Band. I. Pilot screening study of disease prevalence. *Arthritis Rheum*. 1981;24(5):717-21.
- Lau E, Symmons D, Bankhead C, MacGregor A, Donnan S, Silman A. Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong. *J Rheumatol*. 1993;20(7):1133-7.
- Shichikawa K, Inoue K, Hirota S, Maeda A, Ota H, Kimura M, et al. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. *Ann Rheum Dis*. 1999;58(12):751-6.
- Brighton SW, de la Harpe AL, van Staden DJ, Badenhorst JH, Myers OL. The prevalence of rheumatoid arthritis in a rural African population. *J Rheumatol*. 1988;15(3):405-8.
- Silman AJ, Ollier W, Holligan S, Birrell F, Adebajo A, Asuzu MC, et al. Absence of rheumatoid arthritis in a rural Nigerian population. *J Rheumatol*. 1993;20(4):618-22.
- MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis Rheum*. 2000;43(1):30-7.
- McAllister K, Eyre S, Orozco G. Genetics of rheumatoid arthritis: GWAS and beyond. *Open Access Rheumatol*. 2011;3:31-46.
- Frisell T, Holmqvist M, Kallberg H, Klareskog L, Alfredsson L, Askling J. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. *Arthritis Rheum*. 2013;65(11):2773-82.
- Jarvinen P, Aho K. Twin studies in rheumatic diseases. *Semin Arthritis Rheum*. 1994;24(1):19-28.
- Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. *Br J Rheumatol*. 1993;32(10):903-7.
- Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, et al. Gene expression analysis in RA: towards personalized medicine. *Pharmacogenomics J*. 2014;14(2):93-106.
- van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. *Genes Immun*. 2003;4(3):187-196.
- Speed D, Hemani G, Johnson MR, Balding DJ. Improved heritability estimation from genome-wide SNPs. *Am J Hum Genet*. 2012;91(6):1011-21.
- Laki J, Lundstrom E, Snir O, Ronnelid J, Ganji I, Catrina AI, et al. Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis. *Arthritis Rheum*. 2012;64(7):2078-84.
- Teyton L, Lotteau V, Turmel P, Arenzana-Seisdedos F, Virelizier JL, Pujol JP, et al. HLA DR, DQ, and DP antigen expression in rheumatoid synovial cells: a biochemical and quantitative study. *J Immunol*. 1987;138(6):1730-38.
- McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med*. 2011;365(23):2205-19.
- Bartok B, Hammaker D, Firestein GS. Phosphoinositide 3-kinase delta

- regulates migration and invasion of synoviocytes in rheumatoid arthritis. *J Immunol*. 2014;192(5):2063-70.
23. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. *Immunol Rev*. 2010;233(1):233-55.
24. Mateen S, Zafar A, Moin S, Khan AQ, Zubair S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. *Clinica chimica acta; international journal of clinical chemistry*. 2016;455:161-171.
25. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol*. 1996;14:397-440.
26. Semerano L, Minichiello E, Bessis N, Boissier MC. Novel Immunotherapeutic Avenues for Rheumatoid Arthritis. *Trends Mol Med*. 2016;22(3):214-29.
27. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. *Arthritis Res Ther*. 2009;11(5):R142.
28. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. *Arthritis Res Ther*. 2007;9(1):R9.
29. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. *Arthritis Res*. 1999;1(1):81-91.
30. Galeazzi M, Bazzichi L, Sebastiani GD, Neri D, Garcia E, Ravenni N, et al. A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination with methotrexate. *Isr Med Assoc J*. 2014;16(10):666.
31. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database Syst Rev*. 2009;(4):CD007848.
32. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet*. 2010;42(6):508-14.
33. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. *PloS One*. 2012;7(1):e30275.
34. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Res Ther*. 2015;17:212.